At the largest hospital in Brooklyn, doctors are working to address disparities for patients facing advanced heart failure.

AngioDynamics announced today that it launched a new trial evaluating its AlphaVac F18 system in treating pulmonary embolism ...

Multi-channel models enhance cardiotoxicity testing, offering more accurate and human-relevant insights for safer drug ...

The company’s RECOVER-AV trial is intended to further the adoption of its AlphaVac F1885 system in the European market.

Optimizing iPSC differentiation significantly improves in vitro Alzheimer's disease models, leading to more accurate and ...